跳至主要内容
临床试验/NCT02108444
NCT02108444已完成不适用

Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients With Hepatitis B Virus Infection

Peking University1 个研究点 分布在 1 个国家目标入组 107 人开始时间: 2007年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
107
试验地点
1
主要终点
the incidence of hepatitis B virus delayed reactivation

研究概览

简要总结

This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.

详细描述

All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • treatment-naive patients with lymphoma
  • patients with a history of previous exposure to hepatitis B virus (HBV): HBsAg or hepatitis B core antibody (anti-HBc) positive

排除标准

  • HBsAg and HBcAb negative

结局指标

主要结局

the incidence of hepatitis B virus delayed reactivation

时间窗: within one year after withdrawal of prophylactic antiviral therapy

hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy

次要结局

  • Number of patients that achieve a tumor response(within one year after withdrawal of prophylactic antiviral therapy)
  • overall survival rate(within one year after withdrawal of prophylactic antiviral therapy)
  • the incidence of hepatitis B virus related hepatitis flare(within one year after withdrawal of prophylactic antiviral therapy)

研究者

发起方
Peking University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jun Zhu

Chairman of lymphoma department

Peking University

研究点 (1)

Loading locations...

相似试验